Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials

International Journal of Cardiology

Volumn 179, Issue , 2015, Pages 279-287

  Sardar, Partha ^a   Chatterjee, Saurav ^b   Lavie, Carl J ^c   Giri, Jay S ^d   Ghosh, Joydeep ^e   Mukherjee, Debabrata ^a   Lip, Gregory Y H ^f  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e Columbia University of Phys and Surg ^*  (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apixaban; Bleeding; Dabigatran; Meta analysis; New oral anticoagulants; Rivaroxaban

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; DAREXABAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; ANTITHROMBIN; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HIP SURGERY; HUMAN; INTERRATER RELIABILITY; LUNG EMBOLISM; META ANALYSIS (TOPIC); PEER REVIEW; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; META ANALYSIS; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; ANTITHROMBINS; AZEPINES; BENZAMIDES; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; THIAZOLES; THIOPHENES;

EID: 84920677876     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.101     Document Type: Article

References (27)

1. S.S. Adam, J.R. McDuffie, and T.L. Ortel Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Ann. Intern. Med. 157 2012 796 807
2. U.S. Food and Drug Administration. FDA News Release: Nov. 2, 2012. FDA expands use of Xarelto to treat, reduce recurrence of blood clots. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm. Accessed March 12, 2013.
3. European Medicines Agency. Public assessment report for Xarelto. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000944/WC500057109.pdf. Accessed March 12, 2013.
4. National Institute for Health and Clinical Excellence Guideline. Venous thromboembolism - rivaroxaban (TA170). http://guidance.nice.org.uk/TA170. Accessed March 12, 2013
5. European Medicines Agency. Public assessment report for Eliquis. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/002148/WC500107773.pdf. Accessed March 12, 2013.
6. V. Prasad, R.M. Kaplan, and R.S. Passman New frontiers for stroke prevention in atrial fibrillation Cerebrovasc. Dis. 33 2012 199 208
7. B.N. Beasley, E.F. Unger, and R. Temple Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran N. Engl. J. Med. 364 2011 1788 1790
8. European Medicines Agency. Public assessment report for Pradaxa. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000829/WC500041060.pdf. Accessed March 12, 2013.
9. C.S. Miller, S.M. Grandi, and A. Shimony Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am. J. Cardiol. 110 2012 453 460
10. R.S. Kazmi, and B.A. Lwaleed New anticoagulants: how to deal with treatment failure and bleeding complications Br. J. Clin. Pharmacol. 72 2011 593 603
11. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
12. L.H. Rasmussen, T.B. Larsen, and T. Graungaard Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis BMJ 345 2012 e7097 10.1136/bmj.e7097
13. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann. Intern. Med. 18 151 2009 W65 W94
14. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: http://www.cochrane-handbook.org.
15. H.C. Bucher, G.H. Guyatt, and L.E. Griffith The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J. Clin. Epidemiol. 50 1997 683 691
16. B.I. Eriksson, O.E. Dahl, and H.R. Büller BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial J. Thromb. Haemost. 3 2005 103 111
17. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
18. R. Marlu, E. Hodaj, and A. Paris Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers Thromb. Haemost. 108 2012 217 224
19. A. Komócsi, A. Vorobcsuk, and D. Kehl Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials Arch. Intern. Med. 172 2012 1537 1545
20. K.H. Mak Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials BMJ Open 2 5 Oct 6 2012 (pii: e001592)
21. S.B. Deitelzweig, S.C. McKean, and A.N. Amin Prevention of venous thromboembolism in the orthopedic surgery patient Cleve. Clin. J. Med. 75 Suppl. 3 2008 S27 S36
22. D.M. Sobieraj, S. Lee, and C.I. Coleman Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review Ann. Intern. Med. 156 2012 720 727
23. A.T. Cohen, T.E. Spiro, and H.R. Büller MAGELLAN investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients N. Engl. J. Med. 368 2013 513 523
24. S.Z. Goldhaber, A. Leizorovicz, and A.K. Kakkar ADOPT trial investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients N. Engl. J. Med. 365 2011 2167 2177
25. A. Gómez-Outes, A.I. Terleira-Fernández, and M.L. Suárez-Gea Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons BMJ 344 2012 e3675
26. I. Neumann, G. Rada, and J.C. Claro Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Ann. Intern. Med. 156 2012 710 719
27. R. De Caterina, S. Husted, and L. Wallentin Coordinating committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper J. Am. Coll. Cardiol. 59 2012 1413 1425